Healthcare Providers and Services
Company Overview of Mayo Clinic
Mayo Clinic, a not-for-profit medical group practice, provides medical care, research, and education services in Minnesota, Florida, Arizona, Iowa, Georgia, and Wisconsin. It offers medical care services in various specialties, including diabetes and endocrinology, gastroenterology, gynecology, cancer, neurology and neurosurgery, orthopedics, pulmonology, rheumatology, nephrology, urology, and cardiology and heart surgery. The company operates a network of care centers in the United States. It also provides medical education services through schools, offering various degree or certificate programs in continuing medical education, doctoral, master’s, and health sciences. In addition, the comp...
200 First Street SW
Rochester, MN 55905
Founded in 1919
Key Executives for Mayo Clinic
Chief Executive Officer of Mayo Foundation
Compensation as of Fiscal Year 2014.
Mayo Clinic Key Developments
Geron Corporation and Mayo Clinic Enter into a Transfer Agreement
Aug 5 14
On July 31, 2014, Geron Corporation and Mayo Clinic entered into a transfer agreement whereby the Investigational New Drug application for imetelstat under which the investigator-sponsored trial to assess the effect of imetelstat in patients with myelofibrosis has been conducted will be transferred to Geron. In addition, the parties have agreed that Geron will assume responsibility for the conduct of the Myelofibrosis IST as the trial sponsor. In connection with entering into the Transfer Agreement, Mayo Clinic has transferred data from the clinical database for the Myelofibrosis IST to Geron. Subject to completion of the obligations and receipt of the deliverables described in the transfer plan that is part of the Transfer Agreement, Geron and Mayo Clinic agreed that the IND and responsibility for the Myelofibrosis IST as the trial sponsor will be transferred to Geron by September 30, 2014. The Company does not intend to enroll additional patients in the Myelofibrosis IST and plans to continue to conduct the Myelofibrosis IST at Mayo Clinic until the trial is closed. The Transfer Agreement also includes certain indemnifications, including, upon completion of the activities set out in the transfer plan and subject to certain customary exceptions, a release of liability from any and all claims by the company arising from the Transferred Information and the IND.
Amsel Medical Signs Patent License Agreement with Mayo Clinic
Jul 28 14
Amsel Medical Corporation has signed a patent license agreement for certain intellectual property developed by Mayo Clinic, a not-for-profit medical practice. Both the companies are based in the US. Amsel Medical intends to incorporate the licensed intellectual property in the development of the Amsel Occluder device. The Amsel Occluder Device is intended for use on tubular structures or blood vessels wherever a metal ligating clip is indicated and within the size range of 2 millimeters to 7 millimeters diameter. The transaction will allow Amsel Medical to expand its medical patent portfolio regarding The Amsel Occluder device.
ENTEROME Bioscience SA and Mayo Clinic Enter Collaboration to Develop and Commercialize Microbiome-Based Diagnostic Tools for Nutritional Interventions
Jun 17 14
ENTEROME Bioscience SA announced it has entered into an agreement with Mayo Clinic. The collaboration is focused on the discovery and validation of gut microbiome-based diagnostic tests for predicting response to medical nutritional intervention in obese or overweight patients. Enterome's scientific founder Dusko Ehrlich and his collaborators at INRA (French National Institute for Agricultural Research) and ICAN (Institute of Cardiometabolism and Nutrition) have identified a panel of bacterial biomarkers from the gut microbiome (collectively known as MET 230) that enables the stratification of patients based on the health and diversity of their gut microbiome. In a 400-patient study, this panel of biomarkers has been correlated to the metabolic profile of obese patients as well as to their responsiveness to nutritional intervention. From this scientific finding, Enterome, under a license agreement with INRA, is developing a diagnostic test dedicated to the management of obesity and personalization of medical nutrition to patient's needs. It is hoped that the application of Enterome's technology will be a key driver for improving the outcome of stratified nutritional strategies and in the future the development of novel drugs or functional food products aiming to decrease co-morbidities associated to overweight and obesity (that is type 2 diabetes). Mayo Clinic is currently conducting a study to characterize the gut microbiome before and after dietary intervention. If successful this study would enable the commercialization of a nutrition test for patients with obesity associated with low grade inflammation and certain metabolic risk factors.
Similar Private Companies By Industry
Recent Private Companies Transactions